Arcus Biosciences Share Price (NYSE: RCUS)

$10.6

▲

-0.01

(-0.09%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Arcus Biosciences Stock chart to analyse performance

Arcus Biosciences stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$10.41
Today's High:$10.64
$10.60
1.79%
Downside
Day's Volatility :2.16%
Upside
0.38%
52 Weeks Low:$6.50
52 Weeks High:$18.98
$10.60
38.68%
Downside
52 Weeks Volatility :65.75%
Upside
44.15%

Arcus Biosciences Stock Returns

Period	Arcus Biosciences Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	14.86%	3.6%	0.0%
6 Months	0.86%	-7.7%	0.0%
1 Year	-36.09%	-12.6%	0.0%
3 Years	-58.83%	9.5%	-4.7%

Arcus Biosciences Inc Key Stats

Check Arcus Biosciences key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$10.61
Open	$10.64
Today's High	$10.64
Today's Low	$10.41
Market Capitalization	$1.1B
Today's Volume	$548.3K
52 Week High	$18.98
52 Week Low	$6.5
Revenue TTM	$262.0M
EBITDA	$-328.0M
Earnings Per Share (EPS)	$-3.14
Profit Margin	-113.74%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-50.34%

Stock Returns calculator for Arcus Biosciences Stock including INR - Dollar returns

The Arcus Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Arcus Biosciences investment value today

Current value as on today

₹69,255

Returns

₹30,745

(-30.74%)

Returns from Arcus Biosciences Stock

₹36,029 (-36.03%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Arcus Biosciences Stock

10%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Arcus Biosciences Stock from India on INDmoney has increased by 10% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Arcus Biosciences Inc

Name
Holdings %
Name
Holdings %
BlackRock Inc
10.21%
Vanguard Group Inc
6.16%
Point72 Asset Management, L.P.
5.61%
FMR Inc
4.19%
Woodline Partners LP
3.76%
State Street Corp
3.47%

Analyst Recommendation on Arcus Biosciences Stock

Rating

Trend

Buy

83%Buy

16%Hold

0%Sell

Based on 18 Wall street analysts offering stock ratings for Arcus Biosciences(by analysts ranked 0 to 5 stars)

Arcus Biosciences Share Price Target

What analysts predicted

Upside of 167.58%

Target:

$28.36

Current:

$10.60

Arcus Biosciences share price target is $28.36, a slight Upside of 167.58% compared to current price of $10.60 as per analysts' prediction.

Arcus Biosciences Stock Insights

Price Movement
In the last 1 month, RCUS stock has moved up by 12.3%
Increasing Revenue
Revenue is up for the last 3 quarters, 26.0M → 160.0M (in $), with an average increase of 44.8% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -112.0M → -8.0M (in $), with an average increase of 1300.0% per quarter
RCUS vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 108.0%
RCUS vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 168.6%
Price to Sales
ForRCUS every $1 of sales, investors are willing to pay $3.9, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Arcus Biosciences Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$15.0M	↑ 79.58%
Net Income	$-75.9M	↑ 53.11%
Net Profit Margin	-506.21%	↑ 87.52%

	FY20	Y/Y Change
Revenue	$78.0M	↑ 420.0%
Net Income	$-123.0M	↑ 61.99%
Net Profit Margin	-157.69%	↑ 348.52%

	FY21	Y/Y Change
Revenue	$383.0M	↑ 391.03%
Net Income	$53.0M	↓ 143.09%
Net Profit Margin	13.84%	↑ 171.53%

	FY22	Y/Y Change
Revenue	$112.0M	↓ 70.76%
Net Income	$-267.0M	↓ 603.77%
Net Profit Margin	-238.39%	↓ 252.23%

	FY23	Y/Y Change
Revenue	$117.0M	↑ 4.46%
Net Income	$-307.0M	↑ 14.98%
Net Profit Margin	-262.39%	↓ 24.0%

	FY24	Y/Y Change
Revenue	$258.0M	↑ 120.51%
Net Income	$-283.0M	↓ 7.82%
Net Profit Margin	-109.69%	↑ 152.7%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$145.0M	↑ 367.74%
Net Income	$-4.0M	↓ 95.06%
Net Profit Margin	-2.76%	↑ 258.53%

	Q2 FY24	Q/Q Change
Revenue	$39.0M	↓ 73.1%
Net Income	$-93.0M	↑ 2225.0%
Net Profit Margin	-238.46%	↓ 235.7%

	Q3 FY24	Q/Q Change
Revenue	$48.0M	↑ 23.08%
Net Income	$-92.0M	↓ 1.08%
Net Profit Margin	-191.67%	↑ 46.79%

	Q4 FY24	Q/Q Change
Revenue	$26.0M	↓ 45.83%
Net Income	$-94.0M	↑ 2.17%
Net Profit Margin	-361.54%	↓ 169.87%

	Q1 FY25	Q/Q Change
Revenue	$28.0M	↑ 7.69%
Net Income	$-112.0M	↑ 19.15%
Net Profit Margin	-400.0%	↓ 38.46%

	Q2 FY25	Q/Q Change
Revenue	$160.0M	↑ 471.43%
Net Income	$-8.0M	↓ 92.86%
Net Profit Margin	-5.0%	↑ 395.0%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$15.0M	↑ 79.58%

	FY20	Y/Y Change
Profit	$78.0M	↑ 420.0%

	FY21	Y/Y Change
Profit	$383.0M	↑ 391.03%

	FY22	Y/Y Change
Profit	$112.0M	↓ 70.76%

	FY23	Y/Y Change
Profit	$117.0M	↑ 4.46%

	FY24	Y/Y Change
Profit	$258.0M	↑ 120.51%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$145.0M	↑ 367.74%

	Q2 FY24	Q/Q Change
Profit	$39.0M	↓ 73.1%

	Q3 FY24	Q/Q Change
Profit	$48.0M	↑ 23.08%

	Q4 FY24	Q/Q Change
Profit	$26.0M	↓ 45.83%

	Q1 FY25	Q/Q Change
Profit	$28.0M	↑ 7.69%

	Q2 FY25	Q/Q Change
Profit	$160.0M	↑ 471.43%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-73.5M	↑ 70.86%
Investing Cash Flow	$59.2M	↓ 152.2%
Financing Cash Flow	$1.1M	↓ 99.13%

	FY20	Y/Y Change
Operating Cash Flow	$111.2M	↓ 251.33%
Investing Cash Flow	$-434.4M	↓ 833.58%
Financing Cash Flow	$438.7M	↑ 38962.78%

	FY21	Y/Y Change
Operating Cash Flow	$-256.2M	↓ 330.43%
Investing Cash Flow	$-3.9M	↓ 99.11%
Financing Cash Flow	$237.3M	↓ 45.9%

	FY22	Y/Y Change
Operating Cash Flow	$438.0M	↓ 270.98%
Investing Cash Flow	$-413.0M	↑ 10577.35%
Financing Cash Flow	$33.0M	↓ 86.1%

	FY23	Y/Y Change
Operating Cash Flow	$-306.0M	↓ 169.86%
Investing Cash Flow	$194.0M	↓ 146.97%
Financing Cash Flow	$33.0M	↑ 0.0%

	FY24	Y/Y Change
Operating Cash Flow	$-170.0M	↓ 44.44%
Investing Cash Flow	$-84.0M	↓ 143.3%
Financing Cash Flow	$277.0M	↑ 739.39%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-2.0M	↓ 97.73%
Investing Cash Flow	$-169.0M	↓ 703.57%
Financing Cash Flow	$229.0M	↑ 7533.33%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-94.0M	↑ 4600.0%
Investing Cash Flow	$63.0M	↓ 137.28%
Financing Cash Flow	$2.0M	↓ 99.13%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$26.0M	↓ 127.66%
Investing Cash Flow	$-29.0M	↓ 146.03%
Financing Cash Flow	$48.0M	↑ 2300.0%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-100.0M	↓ 484.62%
Investing Cash Flow	$51.0M	↓ 275.86%
Financing Cash Flow	$-2.0M	↓ 104.17%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-132.0M	↑ 32.0%
Investing Cash Flow	$32.0M	↓ 37.25%
Financing Cash Flow	$142.0M	↓ 7200.0%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-133.0M	↑ 0.76%
Investing Cash Flow	$137.0M	↑ 328.13%
Financing Cash Flow	$52.0M	↓ 63.38%

Arcus Biosciences Technicals Summary

Sell

Neutral

Buy

Arcus Biosciences is currently in a neutral trading position according to technical analysis indicators.

Arcus Biosciences Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Arcus Biosciences Inc	15.99%	0.86%	-36.09%	-58.83%	-53.9%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Arcus Biosciences Inc	14.37	NA	NA	-3.71	-0.5	-0.19	NA	5.16
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Arcus Biosciences Inc	Buy	$1.1B	-53.9%	14.37	-113.74%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Organization	Arcus Biosciences
Employees	627
CEO	Dr. Terry J. Rosen Ph.D.
Industry	Health Technology

Key Management of Arcus Biosciences Inc

Name	Title
Dr. Terry J. Rosen Ph.D.	Co-Founder, Chairman & CEO
Dr. Juan Carlos Jaen Ph.D.	Co- Founder & President
Mr. Robert C. Goeltz II	Principal Financial Officer & CFO
Ms. Jennifer A. Jarrett M.B.A.	Chief Operating Officer
Dr. K. Christopher Garcia Ph.D.	Co-Founder & Member of Scientific Advisory Board
Mr. Alexander Azoy CPA	VP of Finance & Principal Accounting Officer
Dr. Jonathan Yingling Ph.D.	Chief Scientific Officer
Pia Eaves	Vice President of Investor Relations & Strategy
Ms. Carolyn C. Tang J.D.	General Counsel & Corporate Secretary
Holli Kolkey	Vice President of Corporate Communications

Important FAQs about investing in RCUS Stock from India :

What is Arcus Biosciences share price today?

Arcus Biosciences share price today is $10.60 as on August 30, 2025 at 1:29 am IST at the close of the market. Arcus Biosciences share today touched a day high of $10.64 and a low of $10.41.

What is the 52 week high and 52 week low for Arcus Biosciences share?

Arcus Biosciences share touched a 52 week high of $18.98 and a 52 week low of $6.50. Arcus Biosciences stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $10.60, lower by 44.15% versus the 52 week high.

How to invest in Arcus Biosciences Stock (RCUS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Arcus Biosciences on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Arcus Biosciences Shares that will get you 0.1415 shares as per Arcus Biosciences share price of $10.60 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Arcus Biosciences Stock (RCUS) from India?

Indian investors can start investing in Arcus Biosciences (RCUS) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Arcus Biosciences stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Arcus Biosciences share’s latest price of $10.60 as on August 30, 2025 at 1:29 am IST, you will get 0.9434 shares of Arcus Biosciences. Learn more about fractional shares .

What are the returns that Arcus Biosciences has given to Indian investors in the last 5 years?

Arcus Biosciences stock has given -53.9% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?